All In Biotech

Drug Trial Radar · NCT07890870

A Study to Evaluate a Single Dose of IBIO-610 in Participant With Obesity.

A Phase I, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBIO-610 in Overweight or Obese Adult Participants.

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Jan 2028

Study completion Jan 2028

Sponsor

Lead sponsor
iBio, Inc.Industry
Sponsor type
Industry
First posted
Oct 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn which dose of study drug IBIO-610 has the right balance of safety, tolerability and impact on body composition in participants with obesity.

Conditions

  • Obesity & Overweight

Interventions

  • IBIO-610Drug

    IBIO-610; subcutaneous injection

  • PlaceboDrug

    Matching placebo; subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of the safety and tolerability of a single dose of IBIO-610; Incidence, severity, and relationship to study treatment of TEAEs and SAEs, as determined by clinical laboratory evaluations, vital signs, physical examinations, and ECGs.Time frame: From Day 1 through Day 252

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Q-Pharm Pty Ltd

    Brisbane, Queensland, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.